ArticleSmall (Weinheim an der Bergstrasse, Germany)2009
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.
Article in Small (Weinheim an der Bergstrasse, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 1 synthesis or guideline pooled it, 356 citations in OpenAlex.
- Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.International journal of molecular sciences · 2021Pooled it
- Breaking Through the Barrier: Nanoparticle-Driven MRI Strategies for Diagnosis and Therapy of Pancreatic Cancer.ACS nanoscience Au · 2026Review
- Metal-Coordinated His-Tag Functionalization of Polymeric Nanogels for Therapeutic Applications.ACS applied nano materials · 2026Article
- A comprehensive review of using nanomaterials in cancer immunotherapy: Pros and Cons of clinical usage.3 Biotech · 2025Review
- Magnetic Cell Targeting for Cardiovascular Tissue Engineering.Tissue engineering. Part B, Reviews · 2025Review
- Biotransformation and biological fate of magnetic iron oxide nanoparticles for biomedical research and clinical applications.Nanoscale advances · 2025Review
- Review
- Click Chemistry-Based Bioconjugation of Iron Oxide Nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody-Gaussia Luciferase Fusion Protein.Pharmaceutics · 2023Article
- Optimizing Conjugation Chemistry, Antibody Conjugation Site, and Surface Density in Antibody-Nanogel Conjugates (ANCs) for Cell-Specific Drug Delivery.Bioconjugate chemistry · 2023Article
- Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.Frontiers in immunology · 2023Review
- Folic acid functionalization for targeting self-assembled paclitaxel-based nanoparticles.RSC advances · 2022Article
- Aptamer-Based Cancer Cell Analysis and Treatment.ChemistryOpen · 2022Review
- Review
- Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.Nano-micro letters · 2021Review
- Impact of Tuning the Surface Charge Distribution on Colloidal Iron Oxide Nanoparticle Toxicity Investigated inNanomaterials (Basel, Switzerland) · 2021Article
- Nanotechnology and its use in imaging and drug delivery (Review).Biomedical reports · 2021Review
- Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography.Journal of clinical medicine · 2021Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Epidermal growth factor receptor (EGFR) targeted nanoparticle are developed by conjugating a single-chain anti-EGFR antibody (ScFvEGFR) to surface functionalized quantum dots (QDs) or magnetic iron oxide (IO) nanoparticles. The results show that ScFvEGFR can be successfully conjugated to the nanoparticles, resulting in compact ScFvEGFR nanoparticles that specifically bind to and are internalized by EGFR-expressing cancer cells, thereby producing a fluorescent signal or magnetic resonance imaging (MRI) contrast. In vivo tumor targeting and uptake of the nanoparticles in human cancer cells is demonstrated after systemic delivery of ScFvEGFR-QDs or ScFvEGFR-IO nanoparticles into an orthotopic pancreatic cancer model. Therefore, ScFvEGFR nanoparticles have potential to be used as a molecular-targeted in vivo tumor imaging agent. Efficient internalization of ScFvEGFR nanoparticles into tumor cells after systemic delivery suggests that the EGFR-targeted nanoparticles can also be used for the targeted delivery of therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.